Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark D Pescovitz

Showing results (41-50 of 63) with videos related to

Pageof 7
Sort By:
British Journal of Clinical Pharmacology|June 9, 2007
Pharmacokinetics, safety, and efficacy of mycophenolate mofetil in combination with sirolimus or ciclosporin in renal transplant patientsMark D Pescovitz, Flavio Vincenti, Marquis Hart, et al.
Journal of Clinical Neuromuscular Disease|June 5, 2009
Rituximab for the treatment of thymoma-associated and de novo myasthenia gravis: 3 cases and reviewRobert P Nelson, Robert M Pascuzzi, Kenneth Kessler, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|January 8, 2005
Rituximab inhibits the in vivo primary and secondary antibody response to a neoantigen, bacteriophage phiX174Christopher M Bearden, Avinash Agarwal, Benita K Book, et al.
Transplantation|November 5, 2010
The clinical utility of whole blood versus plasma cytomegalovirus viral load assays for monitoring therapeutic responseLuiz F Lisboa, Anders Asberg, Deepali Kumar, et al.
Transplantation|June 9, 2005
Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipientsHugh Wiltshire, Carlos V Paya, Mark D Pescovitz, et al.
Clinical Pharmacokinetics|May 6, 2005
Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipientsHugh Wiltshire, Sarapee Hirankarn, Colm Farrell, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 22, 2011
Increased T cell proliferative responses to islet antigens identify clinical responders to anti-CD20 monoclonal antibody (rituximab) therapy in type 1 diabetesKevan C Herold, Mark D Pescovitz, Paula McGee, et al.
Transplantation Reviews (Orlando, Fla.)|April 2, 2011
Therapeutic drug monitoring of mycophenolates in kidney transplantation: report of The Transplantation Society consensus meetingYannick Le Meur, Richard Borrows, Mark D Pescovitz, et al.
Diabetes, Obesity & Metabolism|March 24, 2018
Distinct gene expression pathways in islets from individuals with short- and long-duration type 1 diabetesTeresa L Mastracci, Jean-Valery Turatsinze, Benita K Book, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|November 25, 2003
Equivalent pharmacokinetics of mycophenolate mofetil in African-American and Caucasian male and female stable renal allograft recipientsMark D Pescovitz, Antonio Guasch, Robert Gaston, et al.
Pageof 7

Showing results (41-50 of 63) with videos related to

Sort By:
Pageof 7
British Journal of Clinical Pharmacology|June 9, 2007
Pharmacokinetics, safety, and efficacy of mycophenolate mofetil in combination with sirolimus or ciclosporin in renal transplant patientsMark D Pescovitz, Flavio Vincenti, Marquis Hart, et al.
Journal of Clinical Neuromuscular Disease|June 5, 2009
Rituximab for the treatment of thymoma-associated and de novo myasthenia gravis: 3 cases and reviewRobert P Nelson, Robert M Pascuzzi, Kenneth Kessler, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|January 8, 2005
Rituximab inhibits the in vivo primary and secondary antibody response to a neoantigen, bacteriophage phiX174Christopher M Bearden, Avinash Agarwal, Benita K Book, et al.
Transplantation|November 5, 2010
The clinical utility of whole blood versus plasma cytomegalovirus viral load assays for monitoring therapeutic responseLuiz F Lisboa, Anders Asberg, Deepali Kumar, et al.
Transplantation|June 9, 2005
Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipientsHugh Wiltshire, Carlos V Paya, Mark D Pescovitz, et al.
Clinical Pharmacokinetics|May 6, 2005
Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipientsHugh Wiltshire, Sarapee Hirankarn, Colm Farrell, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 22, 2011
Increased T cell proliferative responses to islet antigens identify clinical responders to anti-CD20 monoclonal antibody (rituximab) therapy in type 1 diabetesKevan C Herold, Mark D Pescovitz, Paula McGee, et al.
Transplantation Reviews (Orlando, Fla.)|April 2, 2011
Therapeutic drug monitoring of mycophenolates in kidney transplantation: report of The Transplantation Society consensus meetingYannick Le Meur, Richard Borrows, Mark D Pescovitz, et al.
Diabetes, Obesity & Metabolism|March 24, 2018
Distinct gene expression pathways in islets from individuals with short- and long-duration type 1 diabetesTeresa L Mastracci, Jean-Valery Turatsinze, Benita K Book, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|November 25, 2003
Equivalent pharmacokinetics of mycophenolate mofetil in African-American and Caucasian male and female stable renal allograft recipientsMark D Pescovitz, Antonio Guasch, Robert Gaston, et al.
Pageof 7